Table 5.
Percentage of resistant isolates from inpatient UTIs against WHO Access antibiotics.
| AMK | AMP | CLI | GEN | NIT | SXT | |
|---|---|---|---|---|---|---|
| Staphylococcus spp. (n = 95) | 16.8% (n = 16) | 97.9% (n = 93) | 68.4% (n = 65) | 10.5% (n = 10) | 6.3% (n = 6) | 20.0% (n = 19) |
| Enterococcus spp. (n = 907) | n.r. | 2.6% (n = 24) | n.r. | 39.3% (n = 356) | 5.8% (n = 53) | n.r. |
| Escherichia coli (n = 1081) | 4.7% (n = 51) | 54.6% (n = 590) | n.r. | 9.3% (n = 101) | 30.9% (n = 335) | 25.2% (n = 273) |
| Klebsiella spp. (n = 685) | 12.8% (n = 88) | n.r. | n.r. | 31.8% (n = 218) | n.r. | 27.8% (n = 274) |
| Citrobacter-Enterobacter-Serratia group (n = 114) | 6.1% (n = 7) | n.r. | n.r. | 17.5% (n = 20) | n.r. | 28.1% (n = 32) |
| Proteus-Providencia-Morganella group (n = 462) | 5.6% (n = 26) | n.r. | n.r. | 14.1% (n = 65) | n.r. | 64.5% (n = 298) |
| Pseudomonas spp. (n = 563) | 16.2% (n = 91) | n.r. | n.r. | 30.3% (n = 171) | n.r. | n.r. |
Abbreviations: amikacin (AMK), ampicillin (AMP), clindamycin (CLI), gentamicin (GEN), nitrofurantoin (NIT), trimethoprim-sulfamethoxazole (SXT), n.r.: not relevant (antibiotics affected by intrinsic resistance mechanisms).